in-PharmaTechnologist.com presents its weekly round-up of the latest chops and changes in the pharmaceutical development and manufacturing industry, including news from Pfizer, Cresset, and Avantor.
Pfizer has named current general counsel Amy Schulman as the new head of its consumer healthcare business.
She replaces Cavan Redmond, who leaves the firm to become CEO of WebMD Health.
Schulman will also retain her role as the pharma firm’s general counsel and president of the nutrition arm.
CEO Ian Read said her appointment will : “enhance the value of our consumer business and strengthen its connection to our biopharmaceutical businesses and pharmacy customers world-wide.”
Cresset BioMolecular Discovery has drafted in David Bardsley as sales director.
He joins the firm – which develops software for calculating and comparing the molecular field characteristics of chemical compounds – from Synergy Health, where he was sales director of the health division.
“This new appointment marks Cresset’s commitment to ensuring companies have the right channels to access software tools and consulting services which are able to streamline their discovery process and tighten their IP position” said Rob Scoffin, CEO.
Bardsley added that he is keen to bring the software to new geographies.
Avantor Performance Materials has appointed John Steitz as its new president and CEO.
Previously, he served as president and chief operating officer at Albemarle Corporation.
He takes over from chairman Rajib Gupta, who served in the position for the chemical maker in the interim.
Matt Holt, MD of investing firm New Mountain Capital, said: "We look forward to working with John as we continue to support an aggressive growth strategy for Avantor. The company is well positioned for long-term success and we are enthusiastic about the possibilities under John's leadership.”
Nancy-Jean Barnabei has become VP and treasurer for developer of drug delivery methods for oncologytherapies, GenSpera.
Barnabei will be responsible for fiscal oversight and financial controls of the company’s operations.
She joins the firm after serving as CFO of Corridor Pharmaceuticals.
“With our company on the cusp of a critical phase of its growth, this is a perfect time for Nancy-Jean Barnabei to join GenSpera,” said Craig Dionne, CEO.
DARA BioSciences has recruited Timothy Heady onto its board of directors.
He takes the role after retiring from UnitedHealthcare Pharmacy in 2011, where he served as CEO.
David Drutz, CEO of DARA said: "His experience in pharmacy and specialty drug management, pharmacy benefits design, and with third-party payers will be of primary relevance to DARA as we continue to grow our oncology-focused specialty pharmaceutical business."
Dyax has hired Ivana Magovcevic-Liebisch as executive VP and chief operating officer.
She first joined the firm in April 2001, and has served as an executive officer since 2005.
Former president of research and development (R&D) at Eleven Biotherapeutics, Burt Adelman, also takes on a new role as chief medical officer. He first joined Dyax in 2012.
“We are delighted to recognize Ivana and Burt's contributions to Dyax and announce their expanded executive roles,” said Gustav Christensen, president and CEO.